FGP
KYMR icon

Freestone Grove Partners’s Kymera Therapeutics KYMR Stock Holding History

Freestone Grove Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Sell
21,176
-135,587
-86% -$11.6M 0.02% 400
2026
Q1 		$13.1M Buy
+156,763
New +$12.4M 0.09% 263

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Freestone Grove Partners's KYMR Position: Q2 2026 in Review

Freestone Grove Partners reduced its Kymera Therapeutics (KYMR) stake by 86% in Q2 2026, selling an estimated $11.6M and leaving 21,176 shares worth $2.43M. The position accounts for 0.02% of the portfolio, ranked #400.

Freestone Grove Partners first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.1M in Q1 2026. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Freestone Grove Partners held 21,176 shares of Kymera Therapeutics worth $2.43M as of Q2 2026.
  • Freestone Grove Partners sold 135,587 Kymera Therapeutics shares in Q2 2026, an estimated $11.6M.
  • Kymera Therapeutics made up 0.02% of Freestone Grove Partners's portfolio in Q2 2026, its #400 holding.
  • Freestone Grove Partners first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Freestone Grove Partners's Kymera Therapeutics position peaked at $13.1M in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.